PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-116.92%
Negative EBIT growth while AGEN is at 21.37%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-185.87%
Negative operating income growth while AGEN is at 21.31%. Joel Greenblatt would press for urgent turnaround measures.
-92.79%
Negative net income growth while AGEN stands at 17.25%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-3998.91%
Negative EPS growth while AGEN is at 23.33%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-3998.91%
Negative diluted EPS growth while AGEN is at 23.33%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
-95.29%
Share reduction while AGEN is at 6.89%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-95.29%
Reduced diluted shares while AGEN is at 6.89%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
No Data
No Data available this quarter, please select a different quarter.
75.47%
Positive OCF growth while AGEN is negative. John Neff would see this as a clear operational advantage vs. the competitor.
66.24%
Positive FCF growth while AGEN is negative. John Neff would see a strong competitive edge in net cash generation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-141.36%
Negative 10Y OCF/share CAGR while AGEN stands at 93.67%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-420.27%
Negative 5Y OCF/share CAGR while AGEN is at 75.91%. Joel Greenblatt would question the firm’s operational model or cost structure.
-362.87%
Negative 3Y OCF/share CAGR while AGEN stands at 61.25%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
-427041.90%
Negative 10Y net income/share CAGR while AGEN is at 90.50%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-659606.65%
Negative 5Y net income/share CAGR while AGEN is 83.24%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-1088784.48%
Negative 3Y CAGR while AGEN is 68.53%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
No Data
No Data available this quarter, please select a different quarter.
-4964.64%
Negative 5Y equity/share growth while AGEN is at 89.49%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-1566.95%
Negative 3Y equity/share growth while AGEN is at 59.44%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1993307.75%
Positive asset growth while AGEN is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
57821.37%
Positive BV/share change while AGEN is negative. John Neff sees a clear edge over a competitor losing equity.
2.24%
Debt growth far above AGEN's 0.86%. Michael Burry fears the firm is taking on undue leverage vs. the competitor.
178.96%
We increase R&D while AGEN cuts. John Neff sees a short-term profit drag but a potential lead in future innovations.
203.49%
We expand SG&A while AGEN cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.